Feasibility of CTLA4Ig gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro.
about
Dendritic cell-based approaches for therapeutic immune regulation in solid-organ transplantationEffects of RNA interference on CD80 and CD86 expression in bone marrow-derived murine dendritic cells.Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?Optimal modes and targets of gene therapy in transplantation.Dendritic cells as promoters of transplant tolerance.Immunoregulatory dendritic cells to prevent and reverse new-onset Type 1 diabetes mellitus.Dendritic cell-based therapy in Type 1 diabetes mellitus.Novel gene therapeutic strategies for the induction of tolerance in cornea transplantation.Dendritic cell therapy for Type 1 diabetes suppression.Dendritic cells expressing soluble CTLA4Ig prolong antigen-specific skin graft survival.Polybrene and interleukin-4: two opposing factors for retroviral transduction of bone-marrow-derived dendritic cells.Adult recurrent respirator papillomatosis: a new therapeutic approach with pegylated interferon alpha 2a (Peg-IFNα-2a) and GM-CSF.Dendritic cells genetically engineered to express IL-4 exhibit enhanced IL-12p70 production in response to CD40 ligation and accelerate organ allograft rejection.Development of a Langerhans cell-targeted gene therapy format using a dendritic cell-specific promoter.Limitations of CD95 ligand-transduced killer dendritic cells to prevent graft rejections.
P2860
Q21284774-9665AF3C-8D57-479B-A660-94E8EE82306AQ33262644-1A8CCA02-EE22-40CF-A371-A391894919B2Q35116303-64917418-E867-47B7-91C1-CD363DC96A08Q35583526-69D94EEB-0376-44BD-BD03-3801A7ED01A0Q36425922-7715B5A4-1CDA-4ECB-92C1-E5D426ECDB6DQ36897372-DE212FE9-8C2E-434B-9DA2-6C118D3B5E53Q37754644-76AF5D8B-6FDE-4F48-B718-C475A6E2CF1BQ37755334-3B339707-5E1D-40A6-B880-A87DB626C3F8Q38059518-5F23545B-3755-4518-A50F-56ED65F7A019Q39712940-FC097863-3D55-4577-8D48-4D72E0CB9D39Q40688948-75BACC73-482D-46C8-BD78-CD3D31CE46E5Q45033281-4EA524AD-88B6-4AB6-B4DF-55DAF18037D2Q45858420-5A981820-502E-45E3-A415-7CE187E4FB48Q45884233-CD686C30-A443-40E7-AC0D-FE9AD34554A6Q46422409-8E9025C8-8813-4C97-8D84-8D943550A8DA
P2860
Feasibility of CTLA4Ig gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Feasibility of CTLA4Ig gene de ...... ecific T cell anergy in vitro.
@en
Feasibility of CTLA4Ig gene de ...... ecific T cell anergy in vitro.
@nl
type
label
Feasibility of CTLA4Ig gene de ...... ecific T cell anergy in vitro.
@en
Feasibility of CTLA4Ig gene de ...... ecific T cell anergy in vitro.
@nl
prefLabel
Feasibility of CTLA4Ig gene de ...... ecific T cell anergy in vitro.
@en
Feasibility of CTLA4Ig gene de ...... ecific T cell anergy in vitro.
@nl
P2093
P2860
P356
P1433
P1476
Feasibility of CTLA4Ig gene de ...... ecific T cell anergy in vitro.
@en
P2093
A E Morelli
A W Thomson
P D Robbins
T Takayama
P2860
P2888
P304
P356
10.1038/SJ.GT.3301244
P577
2000-08-01T00:00:00Z